domingo, 19 de abril de 2020

NIH to launch public-private partnership to speed COVID-19 vaccine and treatment options

Hot Topics of the Day|PHGKB
Coronavirus
Therapeutic Interventions and Vaccines (ACTIV) partnership will develop a collaborative framework for prioritizing vaccine and drug candidates, streamlining clinical trials, coordinating regulatory processes and/or leveraging assets among all partners to rapidly respond to the COVID-19 and future pandemics.
We establish the use of a rapid, non-invasive and cost-effective X-ray-based method as a key diagnosis and screening tool for COVID-19 at early and intermediate stages of the disease. We develop a novel and sophisticated deep learning-based signal and image processing technique as well as classification methodology for analyzing X-ray images.
16 studies were included comprising 3962 patients with COVID-19. Non-severe COVID-19 patients had lower levels for CRP, PCT, IL-6, ESR, SAA and serum ferritin. Moreover, survivors had lower level for IL-6 than non-survivors. This meta-analysis highlights the association of inflammatory markers with the severity of COVID-19.

No hay comentarios:

Publicar un comentario